Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage

Clinical Cancer Research

Volumn 5, Issue 4, 1999, Pages 937-941

  Vikhanskaya, Faina ^a   Colella, Gennaro ^a   Valenti, Monica ^b   Parodi, Silvio ^b   D'Incalci, Maurizio ^a   Broggini, Massimo ^a,c  

^a Molecular Pharmacology Unit   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; COLON CARCINOMA; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; GENE ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

ADENOCARCINOMA; BASE PAIR MISMATCH; CARRIER PROTEINS; CELL CYCLE; CELL SURVIVAL; CISPLATIN; CLONE CELLS; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA DAMAGE; DNA REPAIR; HUMANS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; ONCOGENE PROTEINS, VIRAL; REPRESSOR PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032903655     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Cannistra, S. A. Cancer of the ovary. N. Engl. J. Med., 329: 1550-1559, 1993.
2. NIH. Ovarian Cancer. Screening, Treatment and Followup. NIH Consensus Statement, 12(3): 1-30, 1994.
3. Fink, D., Zheng, H., Nebel, S., Norris, P. S., Aebi, S., Lin, T. P., Nehmè, A., Christen, R. D., Haas, M., MacLeod, C. L., and Howell, S. B. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res., 57: 1841-1845, 1997.
4. Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehmè, A., Christen, R. D., and Howell, S. B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res., 56: 4881-4886, 1996.
5. Anthoney, D. A., McIlwrath, A. J., Gallagher, W. M., Edlin, A. R., and Brown, R. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res., 56: 1374-1381, 1996.
6. Aebi, S., Kurdi-Hadar, B., Gordon, R., Cenni, B., Zheng, H., Fink, D., Christen, R. D., Boland, C. R., Koi, M., Fishel, R., and Howell, S. B. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res., 56: 3087-3090, 1996.
7. Drummond, J. T., Anthoney, D. A., Brown, R., and Modrich, P. Cisplatin and Adriamycin resistance are associated with MutLa and mismatch repair deficiency in an ovarian tumor cell line. J. Biol. Chem., 271: 19645-19648, 1996.
8. 2-terminal kinase and c-abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res., 57: 3253-3257, 1997.
9. Fan, S., Smith, M. L., Rivet, D. J., Duba, D., Zhan, Q., Kohn, K. W., Fornace, A. J. J., and O'Connor, P. M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55: 1649-1654, 1995.
10. Fan, S., Chang, J. K., Smith, M. L., Duba, D., Fornace, A. J., Jr., and O'Connor, P. M. Cells lacking CIPI/WAFI genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene, 14: 2127-2136, 1997.
11. Graniela Siré, E. A., Vikhanskaya, F., and Broggini, M. Sensitivity and cellular response to different anticancer agents of a human ovarian cancer cell line expressing wild-type, mutated or no p53. Ann. Oncol., 6: 589-593, 1995.
12. De Feudis, P., Debernardis, D., Beccaglia, P., Valenti, M., Graniela Siré, E. A., Arzani, D., Stanzione, S., Parodi, S., D'Incalci, M., Russo, P., and Broggini, M. DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status. Br. J. Cancer, 76: 474-479, 1997.
13. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 847-849, 1993.
14. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., and Wyllie, A. H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond.), 362: 849-852, 1993.
15. Debernardis, D., Sire, E. G., De Feudis, P., Vikhanskaya, F., Valenti, M., Russo, P., Parodi, S., D'Incalci, M., and Broggini, M. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res., 57: 870-874, 1997.
16. Koi, M., Umar, A., Chauhan, D. P., Cherian, S. P., Carethers, J. M., Kunkel, T. A., and Boland, C. R. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hLMH1 mutation. Cancer Res., 54: 4308-4312, 1994.
17. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
18. Branch, P., Aquilina, A., Bignami, M., and Karran, P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature (Lond.), 362: 652-654, 1993.
19. Aquilina, G., Hess, P., Fiumicino, S., Ceccotti, S., and Bignami, M. A mutator phenotype characterizes one of the two complementation groups in human cells tolerant to methylation damage. Cancer Res., 55: 2569-2575, 1995.
20. Nelson, W. G., and Kastan, M. B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell Biol., 14: 1815-1823, 1994.
21. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
22. Ko, L. J., Prives, C., Maki, C. G., Huibregtse, J. M., and Howley, P. M. p53: puzzle and paradigm. Cancer Res., 56: 2649-2654, 1996.
23. Chen, X., Ko, L. J., Jayaraman, L., and Prives, C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev., 10: 2438-2451, 1996.
24. Fan, S., el Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fornace, A. J., Jr., Magrath, I., Kohn, K. W., and O'Connor, P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 54: 5824-5830, 1994.
25. Jones, N. A., Brown, R., and Dive, C. Regulation of apoptosis in cisplatin-resistant and -sensitive human ovarian carcinoma cell lines. Proc. Am. Assoc. Cancer Res., 38: 626, 1997.
26. 2-M cell cycle checkpoint arrest following ionizing radiation. Cancer Res., 58: 767-778, 1998.
27. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
28. Brown, R., Clugston, C., Burns, P., Edlin, A., Vasey, P., Vojtesek, B., and Kaye, S. B. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int. J. Cancer, 55: 678-684, 1993.